Results 171 to 180 of about 3,132 (216)
Some of the next articles are maybe not open access.
Efficacy of treatment with faricimab for patients with refractory nAMD
European Journal of OphthalmologyObjective To investigate the efficacy of treatment with faricimab in patients with refractory neovascular age-related macular degeneration (nAMD). Methods A Single-centre, retrospective cohort study was conducted on patients treated ...
Sajjad Mahmood, Clare O'Donnell
exaly +4 more sources
Drugs, 2022 Faricimab (faricimab-svoa; Vabysmo™) is a bispecific antibody that binds to and inhibits both vascular endothelial growth factor (VEGF)-A and angiopoietin-2 (Ang-2). Administered by intravitreal injection, faricimab is being developed by Roche/Genentech for use in the treatment of retinal vascular diseases.
Matt Shirley (7340599)
openaire +3 more sources
Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
Medicina (Lithuania), 2023 Background and Objectives: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody.
Yosuke Harada +2 more
exaly +4 more sources
Global experience of faricimab in clinical settings - a review
Expert Opinion on Biological TherapyFaricimab is a bispecific antibody that acts to reduce neoangiogenesis in exudative retinal vascular disorders. It is approved for use in neovascular age-related macular degeneration and diabetic macular edema. We review the published efficacy and safety of faricimab in clinical settings.A comprehensive literature review was conducted.
Nilesh Kumar +2 more
exaly +4 more sources
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration [PDF]
Pharmaceutics, 2023 Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered the first-line therapeutic strategy for treating macular exudative diseases; including wet age-related macular degeneration (w-AMD) and diabetic macular edema (DME)
Carlo Traverso +2 more
exaly +3 more sources
Clinical Outcomes Following a Switch of Therapy to Faricimab in Patients Affected by Neovascular Age-Related Macular Degeneration [PDF]
Journal of Clinical MedicineObjectives: In this study, we evaluated clinical outcomes following a therapy switch to Faricimab, in a patient cohort affected by neovascular age-related macular degeneration (nAMD), having received prior intravitreal anti-VEGF therapy.
Katrin Lorenz +2 more
exaly +3 more sources
Faricimab: from research to clinical practice
Russian Annals of Ophthalmology, 2023Development of new molecules for anti-angiogenic therapy pursues the following objectives: to increase the interval between injections, which can reduce the treatment burden; to improve the effectiveness of treatment by affecting various links of pathogenesis; to ensure a good safety profile.
Yu.N. Yusef +2 more
openaire +2 more sources
Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta‐analysis [PDF]
Acta OphthalmologicaPolypoidal choroidal vasculopathy (PCV) is an aneurismal type of macular neovascularization that show similarities with age-related macular degeneration and diseases that are part of the pachychoroid disease spectrum.
Jakob Grauslund +2 more
exaly +2 more sources
INTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY
RetinaIn this real-world report, faricimab was well tolerated with a low incidence of intraocular inflammation. Purpose: To report 1-year real-world evidence on intraocular inflammation (IOI) adverse events in patients undergoing faricimab therapy in a ...
Andrea Montesel +9 more
semanticscholar +1 more source